In another study, Kim et al. illustrated that empagliflozin elicited elevations in serum beta-hydroxybutyric acid (BHB) concentrations and concomitantly decreased insulin levels among individuals afflicted with both T2D and CVD, without regard to their glycemic status [59]. This evidence concerns the gene INS and type 2 diabetes mellitus.